Sairiyo Therapeutics Australia

Sairiyo Therapeutics is an Australian biotechnology company focused on the development of novel small molecule therapeutics for cardiovascular and neurological conditions. The company's primary research efforts center on an oral PCSK9 inhibitor designed to manage LDL cholesterol levels as an alternative to injectable monoclonal antibodies. Additionally, Sairiyo has developed a neuroprotection program aimed at reducing secondary brain damage in patients suffering from traumatic brain injury or stroke. In 2017, the company was acquired by Nyrada Inc, which has since advanced Sairiyo's core assets into clinical-stage development. The company's programs are characterized by their focus on high-value targets with the potential for improved patient compliance and accessibility.